NCT00699907View on ClinicalTrials.gov

Effect of Flutamide on Biomarkers in Blood and Tissue Samples From Patients at High Risk of Ovarian Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

127

Participants

Timeline

Start Date

January 31, 2005

Primary Completion Date

November 30, 2012

Study Completion Date

November 30, 2014

Conditions
Ovarian Cancer
Interventions
DRUG

flutamide

Patients receive oral flutamide (125 MG/DAY) once daily for 6 weeks in the absence of unacceptable toxicity.

Trial Locations (1)

85724-5024

University of Arizona Cancer Center, Tucson

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Arizona

OTHER

NCT00699907 - Effect of Flutamide on Biomarkers in Blood and Tissue Samples From Patients at High Risk of Ovarian Cancer | Biotech Hunter | Biotech Hunter